Exercise and Olanzapine-samidorphan

Part of paid clinical trials in New York, New York.

Sponsor
New York State Psychiatric Institute
Study ID
NCT06740890
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Olanzapine-samidorphan + exercise — DRUG
    8 weeks of open label Olanzapine-samidorphan + 4 weeks of aerobic exercise

Study Details

This is a single site trial in 30 patients with schizophrenia, schizoaffective, or bipolar I/II/NOS disorder in which all participants will receive eight weeks of olanzapine and samidorphan (Olz/Sam) plus four weeks of aerobic exercise.

Key Dates

Start date
Jun 26, 2025
Status verified
May 2025
Primary completion
Apr 30, 2027
Completion
Apr 30, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: olanzapine-samidorphan plus exercise

Primary Outcome Measure

Weight [ Time Frame: 4 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
New York State Psychiatric InstituteNew YorkNew York10032
Megan Mayer, BA
[email protected]
646-774-8477

Find similar trials in New York, NY

By condition
Schizophrenia
By specialty
PsychiatryMental healthBehavioral health
By research site
New York State Psychiatric Institute· New York, NY

Related Studies